Arctic Aurora LifeScience. Capturing the value in healthcare innovation ARCTIC FUND MANAGEMENT
|
|
- Alexis Robertson
- 5 years ago
- Views:
Transcription
1 Arctic Aurora LifeScience Capturing the value in healthcare innovation ARCTIC FUND MANAGEMENT
2
3 Arcticc Aurora LifeSciencee Why invest in healthcare? Growth in healthcare is one off the dominating themes for the future. What we know for certain is that we as humans live l longer and that the number off elderly increases dramatically. Agingg population, innovationn and global economicc growth aree the main forces f driving the underlying growth in i healthcare. Healthcare already accounts for 10% of global GDP and future growth is expected to exceed global GDP growth. Diseases are primarily age related, e.g cancer and to meet the demand from a growing population, new medicines are needed. The biotech industry is right now undergoing a transformation based on profound new knowledge in biology and related drug development, resulting in novel therapeutics for previously unmet medical needs. In cancer, scientists are providing new solutions that could transform the treatment into a chronic disease you can live with! In 2014 and 2015 there were more drugs approved in the US than in any of the past 15 years. The likelihood of continued success for the sector is high, new disruptive technologies are entering the market backed with strong balance sheets in the companies. Arctic Aurora LifeSciencee Arctic Aurora LifeScience is a specializedd global healthcare fund investing in primarily public life science companies with focus on Europe and the US. The team are experienced health care specialists with excellent track record from investing in thee public life science sector and with high scientific and industrial competence. By active portfolio management, it offers investors unique exposure to the t growth in the biotech and pharmaceutical industries. The strategy is focused on reaching excess return from investmentss in the biotech sector complemented by investmentss also in thee larger companies such as global pharmaceutical companies. An investment in Arctic Aurora LifeScience provides Exposure to the unique growth in the life science sector through a diversified portfolio Potential to extract excess return from the biotech sector A proven investment strategy withh thorough due diligence of investment opportunities Healthcare is a diversifying asset in a general portfolio A transparent, established fund structure with no long locked in periods Why start investing now? Strong fundamentals with beginning of new era with innovative product development transforming the treatment of diseases. This has attracted high interest from investors in the last 3 years The biotech sector is well funded thanks to record number of IPOs and capital raises Sector rotation and political campaigns ahead of US election have taken valuations down to very attractive levels Large Biotech index has currentlyy (April 2016) lower valuation thann S&P 500, many small biotech with good pipeline priced below cash and Big Pharmaa pipelines almost for free Arctic Aurora LifeScience 1
4 Arctic Aurora LifeScience Investment strategy Active Portfolio Management Investing in biotech and drug development in general requires deep understanding of biology as well as the function of the regulatory and commercial part of drug development, i.e clinical studies and the dynamics between smaller biotech companies and the larger pharmaceutical companies funding the later stages of development and thereby contributing to value creation. Arctic Aurora LifeScience conducts active portfolio management with focus on listed biotech companies supplemented by larger global pharmaceutical companies in both US and EU. Investment philosophy is to build a portfolio of successful companies in the life science sector, based on a thorough due diligence process. Due diligence is a combination of top down where the therapeutic areas of medical and commercial interest are selected. Bottom up the universe is screened for companies owning leading science within the selected therapeutic areas and a deep analysis of those companies are undertaken with the aim of finding the best investment opportunities. To maximize risk/reward we only invest in companies with good clinical data. We do not invest in early stage biotech prior to clinical development in patients. Close contact with management teams is essential The portfolio is constructed in relation to risk and expected return, building a diversified portfolio of approximately holdings. Risks include company specific risks, most importantly drug development risk, liquidity risks and general risks such as currency and political risks. The risk in Arctic Aurora LifeScience will be mitigated by portfolio construction, where company risk and portfolio weight is considered, giving a differentiated exposure. Structure Arctic Aurora LifeScience UCITS fund targeting USD 500 million Domicile Ireland Investor profile: Family Offices, Institutions and retail Fee structure for founding investors: Management fee of 1% and performance fee of 10% measured against the MSCI World/Pharma & Life Science Index Total return Net Index Custodian is BNY Mellon Trust Company (Ireland) Limited Administrator is BNY Mellon Investment Servicing (International) Limited Auditors is Deloitte A senior founding team with broad experience and excellent track record Founder and Chief Investment Officer Ulrica Slåne Bjerke has more than 25 years experience from analyzing and investing in the life science sector. Ulrica has an excellent track record in obtaining significant and repeatable high return of investments Founder Dr Torbjørn Bjerke has had leading positions in the whole chain within drug development, from scientist in international big companies to positions as CSO and CEO for private and public biotech companies taking products to the market Analyst Daniel Bolanowski is an experienced analyst within the life science and healthcare field Arctic Aurora LifeScience 2
5 A team from Arctic Fund Management provides full fundd administration including client support, compliance and risk management Outstanding Advisory Board including 6 senior and veryy successful individuals from the pharmaa and investment industry The team has an extensive global network ncluding executives in the life science industry as well as a profound relation to academia The Team: Ulrica s ROI at AP3: Arctic Aurora LifeScience 3
6 Arctic Aurora LifeScience 4
7
8 Arctic Fund Management AS Haakon VII s gate 5 P.O. Box 1833 Vika NO 0123 OSLO, Norway ARCTIC F U N D M A N A G E M E N T Tel Fax fundinvestor.afm@arctic.com
Eventide Healthcare & Life Sciences Fund
Eventide Healthcare & Life Sciences Fund Presentation June 30, 2017 8/4/17 Eventide Asset Management, LLC. 1 Eventide Funds: At A Glance Founded in 2008 Headquartered in Boston, MA Vision: to offer high
More informationDrug Royalty II $701,420,000. Presentation to: San Diego County Employees Retirement Association
Drug Royalty II $701,420,000 Presentation to: San Diego County Employees Retirement Association November 2010 Profile Business Model Team Investment Criteria To acquire Royalty Streams on established commercialized
More informationArix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017
Arix Bioscience plc Half-Yearly Report and Consolidated Interim Financial Statements Six months ended 30 June 2017 CEO s Statement A vote of confidence in the life science sector In February 2017, Arix
More informationJune Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
More informationCONCISE ANNUAL REPORT 2016 ABN
CONCISE ANNUAL REPORT ABN 24 004 196 909 CONTENTS Chairman s Letter 2 CEO Report 4 Financial Highlights 6 Financial History 7 Directors Report 10 Corporate Governance Statement 46 Concise Financial Report
More informationThe Funding Landscape for Small Biopharma Ventures,
HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations
More informationVISIO CAPITAL. GLOBAL HEALTHCARE: The next generation of investment opportunities?
VISIO CAPITAL GLOBAL HEALTHCARE: The next generation of investment opportunities? Visio Salveo Global Healthcare Fund (USD Long / Short) Visio BCI Global Healthcare Fund (ZAR Long only) AFRICAN EAGLE OWL
More informationBuilding global leaders in healthcare...
Building global leaders in healthcare... Annual report and accounts 2017 ... to deliver transformational treatments for patients Syncona Syncona is a leading FTSE 250 company focused on investing in and
More informationPORTAGE BIOTECH INC.
PORTAGE BIOTECH INC. NEWS RELEASE Portage Provides Additional Information Relating to the Independent Director Review of the Proposed Acquisition of SalvaRx Limited TORONTO, ONTARIO - December 19, 2018
More informationPharma breakthrough. L&G Pharma Breakthrough UCITS ETF. Part of the disruptive technology thematics range
Intended for professional clients only. Pharma breakthrough L&G Pharma Breakthrough UCITS ETF Part of the disruptive technology thematics range Pharma breakthrough L&G Pharma Breakthrough UCITS ETF Key
More informationUDG Healthcare plc Preliminary Results Presentation FY17. London Stock Exchange, 28 th November 2017
UDG Healthcare plc Preliminary Results Presentation FY17 London Stock Exchange, 28 th November 2017 Forward Looking Statements This Presentation has been prepared by UDG Healthcare plc and contains certain
More informationRussell Investments China Equity Fund
Russell Investments China Equity Fund The most comprehensive way to capture opportunities in China FOR PROFESSIONAL CLIENTS ONLY Fund objective The Fund aims to achieve long term capital appreciation by
More informationINTERIM REPORT 1 JULY - 30 SEPTEMBER 2018
INTERIM REPORT 1 JULY - 30 SEPTEMBER 2018 VICORE PHARMA HOLDING AB (PUBL) SUMMARY OF THE PERIOD The rights issue in September was oversubscribed by 33% and the company received SEK 82.4 million before
More informationThird-Quarter 2018 Earnings Call
Third-Quarter 2018 Earnings Call October 24, 2018 2016 Vertex Pharmaceuticals Incorporated Agenda Introduction Michael Partridge, Senior Vice President, Investor Relations Business Highlights Jeff Leiden,
More informationArix Bioscience plc half yearly report for the six months ended 30 June 2018
Arix Bioscience plc half yearly report for the six months ended 30 June 2018 CEO s Statement It has been another positive six months for Arix, a period during which we had a number of encouraging developments
More informationSupplement dated August 14, 2017 to the Prospectus dated February 28, 2017
BioShares Biotechnology Products Fund (NASDAQ: BBP) BioShares Biotechnology Clinical Trials Fund (NASDAQ: BBC) (each a Fund and, together, the Funds ), each a series of ETFis Series Trust I Supplement
More informationEventide Healthcare & Life Sciences Fund Presentation as of March 31, 2018
Q1 2018 Eventide Healthcare & Life Sciences Fund Presentation as of March 31, 2018 5/21/18 Eventide Asset Management, LLC. 1 Eventide Asset Management INVESTMENTS DESIGNED FOR PERFORMANCE AND A BETTER
More information** The operating loss for H is after exceptional costs of 41k relating to the termination of the Biomoti acquisition
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK Tel 01865 784980 Fax 08701 671931 ("Physiomics" or "the Company") Interim Results Statement for the six-month period
More informationABLYNX ANNOUNCES FULL YEAR RESULTS FOR 2007
ABLYNX ANNOUNCES FULL YEAR RESULTS FOR 2007 GHENT, Belgium, 28 February 2008 - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived
More informationHEALTHCARE: INTRODUCTION MAIN ISSUES IDENTIFIED BY THE COMMITTEE:
HEALTHCARE: The Future of Health in Estonia Multi-Sector Collaboration to Ensure Proper Business Climate, Healthy Workforce, and Attractiveness for Current & Future Investment INTRODUCTION The Estonian
More informationReflections on the impact of the financial
Brussels, Belgium, 15 February 2013 Reflections on the impact of the financial and economic crisis ii on health and health systems in the European Region Zsuzsanna Jakab WHO Regional Director for Europe
More informationUDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017
UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationIMS Brogan Private Drug Plan Drug Cost Forecast Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies
IMS Brogan Private Drug Plan Drug Cost Forecast 2013-2017 Commissioned by Rx&D Canada s Research-Based Pharmaceutical Companies Overview 1. Who are Rx&D and IMS Brogan? 2. Environment 3. Background 4.
More informationEventide Healthcare & Life Sciences Fund Presentation as of December 31, Eventide Asset Management, LLC.
Eventide Healthcare & Life Sciences Fund Presentation as of December 31, 2017 2/5/18 Eventide Asset Management, LLC. 1 Eventide Asset Management INVESTMENTS DESIGNED FOR PERFORMANCE AND A BETTER WORLD
More informationWe are in the business of saving lives and returning reason to the pharmaceutical and diagnostic industries.
We are in the business of saving lives and returning reason to the pharmaceutical and diagnostic industries. Contents are provided for general information purposes only and do not constitute an offer to
More informationOverview of Pharmaco- Economics Methodologies Maher Hassoun, M.S.
Overview of Pharmaco- Economics Methodologies Maher Hassoun, M.S. Director of Communications, ISPOR Lebanon Chapter (LSPOR) ISPOR Member Country Manager, Mundipharma Lebanon and Jordan Outline Current
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationBavarian Nordic A/S Notice Convening Ordinary General Meeting
Company Announcement 19 March 2013 Bavarian Nordic A/S Notice Convening Ordinary General Meeting Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby
More informationCOMMITTED TO PEOPLE: PHARMACEUTICAL INDUSTRY CHALLENGES IN EUROPE INNOVATION IN PORTUGAL: BRIEF OVERVIEW
COMMITTED TO PEOPLE: PHARMACEUTICAL INDUSTRY CHALLENGES IN EUROPE INNOVATION IN PORTUGAL: BRIEF OVERVIEW Heitor Costa, Executive Director of APIFARMA July 3 2018 Conference The Portuguese Healthcare system
More informationC API TA L. Executive Summary. ENTO F&B Private Equity Fund DIFC Close-Ended Exempt Fund Regulated by the DFSA
C API TA L Executive Summary ENTO F&B Private Equity Fund DIFC Close-Ended Exempt Fund Regulated by the DFSA Related Parties Fund Manager C API TAL Fund Administrator External Valuer Auditor Investment
More informationQ3 Report Webcast November 1, 2018 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q3 Report 2018 Webcast November 1, 2018 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,026,977,439.38 Fund Inception Date 03/04/2000 Number of Issuers 96 Bloomberg
More informationConstellation Healthcare Technologies Raises $15 Million in AIM IPO
Constellation Healthcare Technologies Raises $15 Million in AIM IPO Overview Houston, Texas-based Constellation Healthcare Technologies, Inc. raised $15.1 million in its recent IPO on the London Stock
More informationTherapeutic Goods Amendment (Pharmaceuticals Transparency) Bill Senate Finance and Public Administration Committee
Therapeutic Goods Amendment (Pharmaceuticals Transparency) Bill 2013 Senate Finance and Public Administration Committee 0 mtaa.org.au Medical technology for a healthier Australia www.mtaa.org.au Level
More informationPowering healthcare provider success
Powering healthcare provider success Now and in the future 38 th Annual William Blair Growth Stock Conference June 12, 2018 TRANSFORMING HEALTHCARE TOGETHER Premier Inc. 2018 1 Forward-looking statements
More informationVectura Group plc Acquisition of Activaero
Vectura Group plc Acquisition of Activaero Chippenham, UK 13 March 2014: Vectura Group plc (LSE: VEC; Vectura or the Company ) announces the acquisition of Activaero GmbH ( Activaero ) for a total consideration
More informationFortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights New York, NY May 10, 2018 Fortress Biotech, Inc. (NASDAQ: FBIO) ( Fortress ), a biopharmaceutical company dedicated
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationGalapagos reports record revenues and increased profitability in 2010
Regulated information 4 March 2011 Galapagos reports record revenues and increased profitability in 2010 Revenues 136.6 M (+29%) Net profit 4.4 M ( 09: 3.0 M) Operating profit 1.0 M ( 09: 1.7 M) Year end
More informationFranklin K2 Alternative Strategies Fund
Franklin Templeton Investment Funds Franklin K2 Alternative Strategies Fund Alternatives Fund Profile Fund Details Inception Date 15 September 2014 Investment Style Alternatives Benchmark(s) 1 ICE BofAML
More informationFinancing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.
Financing sources for life science projects and companies Dr. Aitana Peire May 2017 International Exploitation Training FFH2.0, Prague Venture Valuation Mission Independent assessment and valuation of
More informationRobotics and automation
Intended for professional clients only. Robotics and automation ROBO Global Robotics and Automation GO UCITS ETF Part of the disruptive technology thematics range Robotics and automation ROBO Global Robotics
More informationMedicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note
Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements Samsung Bioepis Methodology Note 1 Contents 1. Overview of the MFE Requirements 2. Decisions 3. Submission Requirements 4. Categories
More informationA Look Inside PAF s Services
A Look Inside PAF s Services Barriers to Accessing Treatment from Patients Assisted through the Genomic Testing Support CareLine Pat Jolley, RN Director, Clinical Initiatives June 27, 2018 P: 800.532.5274
More informationDriving Efficiency by Transforming Biopharmaceuticals Commercial Operations
Driving Efficiency by Transforming Biopharmaceuticals Commercial Operations Belén Garijo Chief Operating Officer Biopharmaceuticals Darmstadt, May 15, 2012 Agenda 1. Introduction 2. New global Commercial
More informationBioInvent issues private placement to US-based healthcare investor Omega Funds in parallel to offering a fully guaranteed rights issue
Press release 16 February 2016 This press release may not be published or distributed, directly or indirectly, in or into the United States, Canada, Hong Kong, Japan, South Africa, Australia or any other
More informationSWK Holdings. May 2012
SWK Holdings May 2012 Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or
More informationFranklin Biotechnology Discovery Fund A (acc) USD
Franklin Discovery Fund A (acc) USD Franklin Templeton Investment Funds Fund Manager Report Equity Product Details 1 Fund Assets $2,125,578,204.37 Fund Inception Date 03/04/2000 Number of Issuers 93 Bloomberg
More informationHealth Sector Dynamics
Issue 1 January 216 Health Sector Dynamics Contents At a glance 1 Expenditure on health 2 Health system characteristics and reforms 6 Recent developments 12 Abbreviations 13 Definitions 13 References 13
More informationGLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
More informationManagement Discussion and Analysis. Three-month and Nine-month Periods ended December 31, DIAGNOS Inc.
Management Discussion and Analysis Three-month and Nine-month Periods ended December 31, 2018 Management Discussion and Analysis This Management Discussion and Analysis ( MD&A ), dated February 27, 2019,
More informationHow Runaway Inequality Is Destroying the American Dream
How Runaway Inequality Is Destroying the American Dream And what we can do about it. Presentation by Sarah Daniels & Daniel Buffington runawayinequality.org -- The Alliance for Economic Justice Outline
More informationAlternative Investment Strategies
Alternative Investment Strategies Bringing together opportunities across the alternative investments spectrum to meet investor goals August 2018 For professional investors only. Switzerland: For Qualified
More informationPresentation to Arctic Energy Summit: Investment Decisions in the Arctic The Nexus of Energy, Climate and Business
Guggenheim Partners Presentation to Arctic Energy Summit: Investment Decisions in the Arctic The Nexus of Energy, Climate and Business September 18, 2017 Please see disclosures and legal notice Investment
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Alistair Macdonald Chief Executive Officer January 8, 2019 Forward-Looking Statements, Non-GAAP Financial Measures, and Basis of Financial Presentation Forward-Looking
More informationThe Impact of Future Healthcare Reform on MedTech Communications
J. Robert Paulson President & CEO NxThera, Inc. The Impact of Future Healthcare Reform on MedTech Communications Perspectives From an Early-Stage Medical Device Company The Impact of Future Healthcare
More informationBackground The Health Impact Fund (HIF) Characteristics of the HIF Progress
1 Background The Health Impact Fund (HIF) Characteristics of the HIF Progress 2 Millions of patients lack access to the optimal medicines because of high prices made possible by patent protection. Low
More informationOVERVIEW LORING WARD. A Better Wealth Experience FINANCIAL PROFESSIONAL USE ONLY
OVERVIEW LORING WARD A Better Wealth Experience FINANCIAL PROFESSIONAL USE ONLY A Comprehensive Advisor Solution for Your Practice Today s Advisors and their clients require a comprehensive approach. Build
More informationEventide Multi-Asset Income Fund
Eventide Multi-Asset Income Fund Presentation June 30, 2017 8/18/17 Eventide Asset Management, LLC. 1 Eventide Funds: At A Glance Founded in 2008 Headquartered in Boston, MA Vision: to offer high performance
More informationDecember COMMUNITY CHECKUP CHART PACK
December 2017 2017 COMMUNITY CHECKUP CHART PACK 2 Washington State Performance for Commercially Insured as Compared to NCQA National Benchmarks 3 Washington State Performance for Medicaid Insured as Compared
More informationValue Added Tax Specialists
Value Added Tax VALUE ADDED TAX Value Added Tax Specialists Brendan F. Moore, President, Ryan International, European and Asia-Pacific Operations, leads a team of seasoned value added tax professionals
More informationANNUAL RESULTS 2015: END-OF-YEAR CASH POSITION OF 60M AND MAJOR PROGRESS IN THE DIAGNOSIS AND THE TREATMENT OF NASH
ANNUAL RESULTS 2015: END-OF-YEAR CASH POSITION OF 60M AND MAJOR PROGRESS IN THE DIAGNOSIS AND THE TREATMENT OF NASH Cash horizon to early 2017 Phase IIb clinical results for Elafibranor in NASH led to
More informationResults for the fourth quarter and full year Establishing a Specialty Pharma company
Results for the fourth quarter and full year 2011 Establishing a Specialty Pharma company 16 February 2012 Highlights for the fourth quarter and full year 2011 Photocure (OSE: PHO), a Norwegian specialty
More informationMANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2018 HLS
MANAGEMENT S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2018 HLS Therapeutics Inc. ( HLS or the Company ) was formed on March 12, 2018 by the amalgamation of HLS Therapeutics Inc. ( former
More informationMolecular Partners' IPO bookbuilding resumes with support from Allergan as well as other anchor investors
This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular, this release and the information
More informationXTL BIOPHARMACEUTICALS REPORTS THIRD QUARTER 2015 RESULTS AND CONFIRMS INTENTION TO START LUPUS TRIAL IN 2016
XTL BIOPHARMACEUTICALS REPORTS THIRD QUARTER 2015 RESULTS AND CONFIRMS INTENTION TO START LUPUS TRIAL IN 2016 RAANANA, ISRAEL - (December 1, 2015) (NASDAQ: XTLB, TASE: XTL) ( XTL or the Company ), a clinical-stage
More informationScope of Practice & Compensation Report for the Regulatory Profession
2014 Scope of Practice & Compensation Report for the Regulatory Profession 2014 Scope of Practice & Compensation Report for the Regulatory Profession 1 Contents Introduction... 2 About RAPS... 2 The Survey:
More informationSecurities (the Fund ) Virtus LifeSci Biotech Clinical Trials ETF Virtus LifeSci Biotech Products ETF
BZX Information Circular 17-112 EDGA Information Circular 17-112 BYX Information Circular 17-112 EDGX Information Circular 17-112 Date: September 8, 2017 Re: ETFis Series Trust I Pursuant to the Rules
More informationARK Genomic Revolution Multi-Sector ETF
November 30, 2017 ARK Genomic Revolution Multi-Sector ETF NYSE Arca, Inc: ARKG Summary Prospectus Before you invest, you may want to review the Fund s prospectus, which contains more information about
More informationAdvicenne 2017 Financial Results and Operational Perspectives for 2018
2017 Full-year results and business update Advicenne 2017 Financial Results and Operational Perspectives for 2018 Nîmes, France, April 10 th, 2017 Advicenne (Euronext : ADVIC), a specialist pharmaceutical
More informationVALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company
VALUING YOUR OPPORTUNITY How industry and investors evaluate your project or company Dr. Patrik Frei September 2015 Brisbane Overview Introduction Valuation of start-up companies Valuation of a therapeutic
More informationBridging the Gap in Deal Valuation. Wednesday April 12, 2017
Bridging the Gap in Deal Valuation Wednesday April 12, 2017 Bridging the Gap in Deal Valuation Speakers: Clare Fisher, Vice President, Interim Head of Transactions, Shire Greg Miller, MBA, MPH, Vice President
More informationEuropean Month of the Brain Horizon DG Research & Innovation Unit F2 Medical Research Neurosciences
European Month of the Brain Horizon 2020 DG Research & Innovation Unit F2 Medical Research Neurosciences Issues at stake of brain research Understanding the human brain and its diseases remains one of
More informationEstablishing a Clinical Trials Finance Facility
Establishing a Clinical Trials Finance Facility Finance and licensing proposal October 2008 Overview Market Assessment Traditional equity funding model for pharmaceutical R&D under systemic pressure because
More informationCode on Global Interactions. with Healthcare Professionals
Code on Global Interactions with Healthcare Professionals 2 Table of Contents Introduction... 5 Anti-Bribery Anti-Corruption... 6 Guiding Principles... 7 Promotional Activities... 8 Healthcare Professionals
More informationPharma M&A is Too Expensive: Now What?
Pharma M&A is Too Expensive: Now What? Cheap capital puts pressure on large firms to do something, and in most cases acquiring companies (at a price) can appear quicker and easier than building them. M&A
More informationHilton Capital Management FOCUSED. DILIGENT. DRIVEN.
Hilton Capital Management FOCUSED. DILIGENT. DRIVEN. Hilton Capital Management is a boutique asset manager founded in 2001. With over $635 million in assets under management, the firm s mission is to seek
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationCertified Investment Fund Director Programme SPRING 2016
Certified Investment Fund Director Programme SPRING 2016 Raising professional standards in investment fund governance internationally. A few words from Dr Margaret Cullen, Chief Executive Officer, Certified
More informationRobotics and automation
Intended for professional clients only. Robotics and automation L&G ROBO Global Robotics and Automation UCITS ETF Part of the disruptive technology thematics range Robotics and automation L&G ROBO Global
More informationBeyond Traditional Infrastructure Investing: Listed Infrastructure Equities as an Income Solution
October 2018 Beyond Traditional Infrastructure Investing: Listed Infrastructure Equities as an Income Solution James A. Lydotes, CFA, Brock A. Campbell, CFA & William J. Adams Standish, Mellon Capital
More informationGICS Consultation 2005
GICS Consultation 2005 Standard & Poor s and MSCI Consultation Paper on Potential Changes to the Global Industry Classification Standard (GICS ) Structure I. INTRODUCTION MSCI and Standard & Poor s (S&P),
More informationASX ANNOUNCEMENT CELLMID LIMITED NOTES TO THE APPENDIX 4C. Highlights for the quarter ending 31 December 2018
ASX ANNOUNCEMENT CELLMID LIMITED NOTES TO THE APPENDIX 4C Highlights for the quarter ending 31 December 2018 Record sales achieved during the second quarter of FY2019 at $2.2 million, up 8% from the same
More informationOttawa Hospital Research Institute
Financial statements of Ottawa Hospital Research Institute Table of contents Independent Auditor s Report... 1-2 Statement of financial position... 3 Statement of operations... 4 Statement of changes in
More informationPhysiomics plc. ("Physiomics") or ("the Company")
The Magdalen Centre The Oxford Science Park Robert Robinson Avenue Oxford OX4 4GA UK 27 th March 2018 ("Physiomics") or ("the Company") Issue of Options The Company considers that the award of options
More informationPRESS RELEASE For release in UK and Austria Not for release in the United States of America
PRESS RELEASE For release in UK and Austria Not for release in the United States of America PIMCO AND SOURCE ANNOUNCE THE LAUNCH OF THREE FIXED INCOME ETFs: PIMCO Euro Enhanced Short Maturity Source ETF,
More informationSareum Holdings plc. Paper on lead candidate CHK1 published in high-impact journal. Update. 23 July 2015 HYBRIDAN LLP
Update 23 July 2015 Key Statistics Code : SAR Listing : AIM Sector : Pharmaceuticals & Biotech Market Cap FD : 6m Shares in issue FD : 2,487.4m Current Price : 0.245 12 mnth High/Low : 0.6p/0.205p Stock
More informationThe Poliwogg BioPharma M&A Index
The Poliwogg BioPharma M&A Index Q4 2016 Industry Background Scientific Innovations Driving Opportunities: Increasing Understanding of Disease Mechanism Genomics Enabling Precision Medicine Better Therapeutics
More informationConduct proprietary research Set up & down price targets Document and present investment recommendation
FOR PROFESSIONAL CLIENTS AND, IN SWITZERLAND, FOR QUALIFIED INVESTORS ONLY. IN THE MIDDLE EAST, PROVIDED SOLELY FOR USE BY THE INTENDED RECIPIENT. Mellon Dynamic Large Cap Value Strategy All information
More informationHow to value your start-up Dr. Patrik Frei January 2016 San Francisco
How to value your start-up Dr. Patrik Frei January 2016 San Francisco Overview Introduction to Valuation Valuation of start-up companies Valuation of a therapeutic Product Q & A 2 Venture Valuation Mission
More informationALTERNATIVE INVESTMENT SOLUTIONS SERVE INVESTOR NEEDS AND UNCOVER A GROWTH OPPORTUNITY
ALTERNATIVE INVESTMENT SOLUTIONS SERVE INVESTOR NEEDS AND UNCOVER A GROWTH OPPORTUNITY DIVERSIFY CLIENT ASSETS AND DIFFERENTIATE YOUR BUSINESS COMPREHENSIVE AND FLEXIBLE ALTERNATIVE INVESTMENT SOLUTIONS
More informationValuing Medical Innovation Perspectives matter. Lara Verdian 10 September 2015
Valuing Medical Innovation Perspectives matter Lara Verdian 10 September 2015 1965 1967 1969 1971 1973 1975 1977 1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013
More informationHealthcare in China The Opportunity for Investment. Chindex International and United Family Healthcare February 2010
Healthcare in China The Opportunity for Investment Chindex International and United Family Healthcare February 2010 Forward Looking Statements This presentation contains information which may be considered
More informationLeveraging New Business Models to Improve Value
Leveraging New Business Models to Improve Value Kenneth Kaufman, Kaufman Hall June 24, 2014 Today s Agenda 1. The Macro Economic Issues Driving Real Change in Healthcare 2. The Statistical Picture 3. The
More informationFunding opportunities for EFA members
Funding opportunities for EFA members Roberta Savli EFA EU Policy and Project Officer roberta.savli@efanet.org David Brennan EFA Junior EU Policy and Project Officer info@efanet.org www.efanet.org Financial
More informationBioCryst Pharmaceuticals and Idera Pharmaceuticals File Preliminary Proxy Statement and Investor Presentation in Connection with Pending Merger
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: BioCryst
More informationEventide Multi-Asset Income Fund
Eventide Multi-Asset Income Fund Presentation September 30, 2016 11/17/16 Eventide Asset Management, LLC. 1 Eventide Funds: At A Glance Founded in 2008 Headquartered in Boston, MA Vision: to offer high
More informationPowering healthcare provider success
Powering healthcare provider success Now and in the future Investor Information September 2018 TRANSFORMING HEALTHCARE TOGETHER Premier Inc. 2018 1 Forward-looking statements and non-gaap financial measures
More informationTHE MONTHLY RESEARCH CONFERENCE CALL HEALTHCARE: SECTOR FUNDAMENTALS STILL HEALTHY ARGUS MODERATORS. Jim Kelleher, CFA Director of Research
TH MONTHLY RSARCH CONFRNC CALL HALTHCAR: SCTOR FUNDAMNTALS STILL HALTHY ARGUS MODRATORS Jim Kelleher, CFA Director of Research John M. ade President, Director of Portfolio Strategies David Toung Senior
More information